Skip to main content
倍益康 logo

倍益康 — Investor Relations & Filings

Ticker · 920199 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 360 across all filing types
Latest filing 2026-05-07 Share Issue/Capital Cha…
Country CN China
Listing Beijing Stock Exchange 920199

About 倍益康

https://www.qlbeoka.com/

Beiyikang focuses on the research, development, and manufacturing of rehabilitation and physical therapy equipment. The company integrates professional medical technology with consumer-oriented health solutions. Its product lineup features percussive massage devices, oxygen concentrators, blood pressure monitors, and specialized physical therapy instruments for pain relief and muscle recovery. By utilizing advanced manufacturing processes and technological innovation, Beiyikang delivers products for sports recovery, clinical rehabilitation, and personal health management. The company prioritizes the incorporation of smart technology into its hardware to improve therapeutic outcomes and user experience across its range of recovery and wellness devices.

Recent filings

Filing Released Lang Actions
库存股注销完成暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of cancellation of treasury shares and the resulting change in share capital. It details the repurchase plan, the number of shares canceled, changes in shareholding structure, and subsequent administrative steps. There is no financial data, earnings information, or management discussion. The document is a formal disclosure of a share capital change event, specifically the cancellation of treasury shares, which fits the category of Share Issue/Capital Change announcements. The document length is short (1705 characters), and it is not a report or a certification but a direct announcement of a capital change event.
2026-05-07 Chinese
关于补选第四届董事会审计委员会委员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the by-election of a member to the company's audit committee of the board of directors. It details the appointment of a new audit committee member, the committee's composition after the appointment, and confirms compliance with relevant laws and company governance rules. There is no financial data, no report attached or referenced as being published, and no mention of a general meeting or shareholder vote results. The content focuses on board/management changes specifically related to the audit committee membership. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear and direct content about board committee membership change.
2026-05-06 Chinese
第四届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the eighth meeting of the fourth board of directors of Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal to supplement the audit committee members. The content focuses on board-level decisions and governance matters, specifically about board committee membership changes. There is no financial data, earnings information, or report publication mentioned. The document is not a full report but an announcement of board/management information, specifically about changes in the board's audit committee composition. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and content support this classification with high confidence.
2026-05-06 Chinese
第四届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from the company's board of directors. It details the meeting date, attendance, and the approval of the company's 2026 first quarter report. It references the actual quarterly report being disclosed separately on the exchange platform (announcement 2026-048). The document itself does not contain the financial statements or substantive financial data of the quarterly report but is a formal announcement of the board's approval of that report. Therefore, this document is best classified as Board/Management Information (MANG) because it announces board decisions and meeting resolutions rather than the report itself.
2026-04-28 Chinese
2025年年度报告业绩说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2025 Annual Report. It references the 2025 Annual Report published earlier (announcement number 2026-021) and provides details about the meeting time, location, participants, and how investors can join and submit questions. The document itself does not contain the annual report or detailed financial data but serves as an announcement for the upcoming investor presentation event focused on the annual report results. According to the classification rules, such a document is best classified as an Investor Presentation (IP) because it is a detailed presentation event for investors focusing on financials and company performance, not the report itself or a simple announcement of report publication (which would be RPA). The document length is short but contains substantive information about the event, not just a brief notice or link to a report. Therefore, the appropriate classification is IP with high confidence.
2026-04-27 Chinese
东莞证券股份有限公司关于四川千里倍益康医疗科技股份有限公司向不特定合格投资者公开发行股票之保荐工作总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "保荐工作总结报告书" which translates to "Sponsorship Work Summary Report" related to the public issuance of shares by Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It details the sponsorship institution's duties, including due diligence, continuous supervision, changes in sponsorship representatives, adjustments in the use of raised funds, and evaluations of the issuer's compliance and cooperation. The document is a summary report by the sponsor on their work during the issuance process and continuous supervision period, not the actual issuance prospectus or financial report. It is a detailed report on the sponsorship and supervision activities related to a capital raising event, which aligns with a Capital/Financing Update (CAP) category rather than an Annual Report, Audit Report, or Regulatory Filing. The document length is under 5,000 characters but contains substantive content about the sponsorship work and fundraising usage changes, not merely an announcement or a certification. Therefore, the best fit is Capital/Financing Update (CAP).
2026-04-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.